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A B S T R A C T 
Introduction: In Hong Kong, the prevalence of 
atherosclerotic cardiovascular disease has increased 
markedly over the past few decades, and further 
increases are expected. In 2008, the Hong Kong 
Cardiovascular Task Force released a consensus 
statement on preventing cardiovascular disease 
in the Hong Kong population. The present article 
provides an update on these recommendations. 
Participants: A multidisciplinary group of clinicians 
comprising the Hong Kong Cardiovascular Task 
Force—10 cardiologists, an endocrinologist, and a 
family physician—met in September 2014 and June 
2015 in Hong Kong. 
Evidence: Guidelines from the American College 
of Cardiology/American Heart Association, the 
European Society of Hypertension/European 
Society of Cardiology, and the Eighth Joint National 
Committee for the Management of High Blood 
Pressure were reviewed.
Consensus Process: Group members reviewed 
the 2008 Consensus Statement and relevant 
international guidelines. At the meetings, each 
topical recommendation of the 2008 Statement was 
assessed against the pooled recommendations on 
that topic from the international guidelines. A final 
recommendation on each topic was generated by 
consensus after discussion. 
Conclusions: It is recommended that a formal risk 
scoring system should be used for risk assessment 
of all adults aged 40 years or older who have at least 
one cardiovascular risk factor. Individuals can be 
2016 Consensus statement on prevention of 
atherosclerotic cardiovascular disease in the 
Hong Kong population
Introduction
Atherosclerotic cardiovascular disease (ASCVD), 
which includes coronary heart disease (CHD), 
peripheral vascular disease and stroke, is currently 
one of the most common causes of morbidity and 
mortality worldwide.1 Unfortunately the prevalence 
of ASCVD is expected to increase further over 
the next few decades due to a number of factors 
including an ageing population and increasing 
industrialisation. The latter is associated with 
increased exposure to known ASCVD risk factors 
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such as smoking, low levels of physical activity, and 
poor dietary habits such as reduced consumption 
of fruit and vegetables and increased fat and salt 
intake.2 
 In Hong Kong, the prevalence of ASCVD risk 
factors has increased markedly over the past few 
decades. For example, the 2005-2008 Hong Kong 
Cardiovascular Risk Factor Prevalence Study-3 
(CRISPS-3) reported an 8.6% increase in the 
prevalence of abdominal obesity (waist circumference 
≥90 cm in men and ≥80 cm in women) and a 21.5% 
MEDICAL PRACTICECME
classified as having a low, moderate, or high risk of 
developing atherosclerotic cardiovascular disease, 
and appropriate interventions selected accordingly. 
Recommended lifestyle modifications include 
adopting a healthy eating pattern; maintaining a low 
body mass index; quitting smoking; and undertaking 
regular, moderate-intensity physical activity. 
Pharmacological interventions should be selected as 
appropriate after lifestyle modification. 
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2016年香港預防動脈粥樣硬化性心血管疾病的
共識聲明
張文勇、鄭俊豪、劉柱柏、王國耀、馬青雲、朱偉星、 
何鴻光、李麗芬、謝鴻發、王壽鵬、甄秉言、甄榮達
引言：香港動脈粥樣硬化性心血管疾病的患病率在過去數十年顯著
增加，預期患者人數還會進一步上升。香港心血管工作小組（Hong 
Kong Cardiovascular Task Force；HKCTF）於2008年發表了一份關
於香港預防動脈粥樣硬化性心血管疾病的共識聲明。本文提供了有關
建議的更新。
參與者：HKCTF是由10名心臟病學、1名內分泌學和1名家庭醫學專
科醫生組成的多學科小組。他們於2014年9月和2015年6月在香港舉
行會議。
證據：建議主要基於以下學會制定的指引：美國心臟病學會／美國心
臟協會、歐洲高血壓學會／歐洲心臟病學會和第八屆聯合全國高血壓
管理委員會。
共識過程：小組成員基於2008年的共識聲明以及相關國際指引進行審
查。會議上根據國際指引中的匯總建議來評估2008年發表的每一項共
識聲明。小組成員參與共識的討論制定，以協商方式達成每一項推薦
建議。
結論：建議對所有40歲或以上至少有一項心血管危險因素的成年人，
利用正式的動脈粥樣硬化性心血管疾病的風險評估系統進行評估，把
病人分為低度、中度或高度風險，並選擇相應適當干預。所推薦的生
活方式改變包括培養健康飲食習慣、保持體重指數於低水平、戒菸、
並定期進行中等強度的體力運動。改變生活方式後才進行藥物治療。
increase in the prevalence of hypertension among 
a cohort of 1803 subjects recruited from CRISPS-
1, the first such survey conducted between 1995 
and 1996.3 Of the 551 participants of the Hong 
Kong Cardiovascular Task Force Risk Management 
Programme, 65.4% had hypertension, 63.7% 
dyslipidaemia, and 33.3% diabetes at baseline (BMY 
Cheung, unpublished data). 
 Global efforts are underway to promote 
ASCVD prevention and reduce the risk of major 
ASCVD events. These efforts have yielded benefits—
between 1990 and 2013, a substantial reduction in 
cardiovascular mortality was seen in central Europe 
(5.2%) and western Europe (12.8%), attributed 
primarily to birth cohorts’ decreased exposure to 
tobacco smoking, improvements in diet, improved 
treatment of cardiometabolic risk factors, and 
improved treatment of CVD.4
Methods
A multidisciplinary group of clinicians comprising 
the Hong Kong Cardiovascular Task Force—10 
cardiologists, an endocrinologist, and a family 
physician—met in September 2014 and June 2015 
in Hong Kong with the aim of updating the first 
Consensus Statement on Preventing Cardiovascular 
Disease in the Hong Kong Population published 
in 2008.5 Prior to the consensus meetings, group 
members reviewed the 2008 Consensus Statement 
and relevant guidelines from the American College 
of Cardiology/American Heart Association, the 
European Society of Hypertension/European 
Society of Cardiology, and the Eighth Joint National 
Committee for the Management of High Blood 
Pressure, among others.5-9 At the meetings, each 
topical recommendation of the 2008 Statement 
was assessed against the pooled recommendations 
on that topic from the international guidelines 
reviewed. A final recommendation on each topic 
was generated by consensus after discussion. 
 The recommendations included in this 
consensus statement constitute the consensus 
opinion of the members of the Hong Kong 
Cardiovascular Task Force regarding the most 
appropriate interventions for the Hong Kong 
population.
Recommendations
Risk assessment
Total cardiovascular risk
Total ASCVD risk is based on the complex 
interactions of a number of different risk factors 
that together have a multiplicative effect. That is, 
the risk of ASCVD is amplified to a greater extent 
by the interaction of multiple risk factors than would 
be expected due to the cumulative effect of each risk 
factor alone.7,9 The present standard of practice for 
the primary prevention of ASCVD is to determine 
a patient’s total ASCVD risk using a formal risk 
scoring algorithm.1,7,9
Who to assess?
In Hong Kong, it is recommended that ASCVD 
prevention efforts should be focused on adults aged 
40 years or older who have at least one ASCVD risk 
factor.1,9 The total ASCVD risk should be formally 
calculated for such individuals, and they should 
receive ASCVD prevention advice and/or treatment 
according to their determined level of risk (high, 
moderate, or low).1,9 High-risk patients will benefit 
most from treatment and include:
•	 patients	 with	 overt	 ASCVD	 (CHD,	 previous	
myocardial infarction, previous stroke, or 
peripheral vascular disease) or those who are 
symptomatic (eg have experience with angina)
•	 patients	with	diabetes	mellitus
•	 patients	 with	 one	 major	 ASCVD	 risk	 factor	
(eg moderate-to-severe hypertension, severely 
elevated lipid levels)9
 These patients automatically meet the 
threshold for intensive risk factor treatment and 
need not undergo formal risk scoring.1,9
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How to assess?
It is important to note that the current 
recommendations do not espouse a preference 
for any particular method of risk projection, but 
recommend that formal ASCVD risk scoring should 
be performed for all potentially at-risk patients. 
 A patient’s 10-year (total) risk for ASCVD may 
be calculated using a variety of methods. The most 
recently published algorithm uses the American 
Pooled Cohort Risk Assessment Equations that are 
sex- and race-specific estimates for African-American 
and White men and women aged 40 to 79 years. They 
utilise age, total and high-density lipoprotein (HDL) 
cholesterol, systolic blood pressure (BP), diabetes, 
and current smoking status to calculate the total 
ASCVD risk.1 The European Systematic Coronary 
Risk Evaluation (SCORE) system is another well-
validated system that uses sex, age, systolic BP, total 
cholesterol, and current smoking status to predict 
the risk of fatal cardiovascular events.7 Another risk 
assessment system, QRISK2, includes the risk factor 
of ‘self-assigned ethnicity’ (including Chinese) in the 
computation10,11; however, the model was validated 
for Chinese immigrants to the United Kingdom and, 
thus, its applicability to the local Chinese population 
is unknown.
 The calculated risk score is used to stratify 
patients into low-, moderate-, and high-risk 
categories (Fig). When interpreting these scores, 
the clinician should bear in mind that they were 
developed and validated for western populations. In 
addition, it must be remembered that any calculated 
ASCVD score is simply an indicator of total 
cardiovascular risk.9 Although it can guide patient 
treatment, it cannot be a substitute for individualised 
patient evaluation and management. The clinician is 
advised to take all factors into account and to treat 
the patient individually rather than treat the risk 
score.
Risk interventions 
There is robust scientific evidence that the 
development of ASCVD in at-risk patients 
may be slowed and/or prevented by lifestyle 
modification, reduction of metabolic risk factors, 
and pharmacological treatment.7,9-19 Listed below are 
FIG.  Algorithm for stratifying patients into low-, moderate-, and high-risk categories
Abbreviations: ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular ; DM = diabetes mellitus; HTN = hypertension; 
OCP = oral contraceptive pill
Evaluation
Alcohol intake Blood pressure
Body mass index CV history
Diet Fasting blood glucose
Fasting lipids OCP use
Physical activity Smoking status
Waist circumference
High-risk assessment
At high risk
Overt ASCVD
Diabetic
One major risk factor
High risk
Achieve optimal weight
Cardioprotective drug therapy
Dietary changes
Exercise regularly
Quit smoking
Treat HTN, DM
Treat with lipid-lowering agent
Moderate risk
Achieve optimal weight
Dietary changes
Exercise regularly
Quit smoking
Treat HTN, DM (if present)
Treat with abnormal lipids (if present)
Low risk
Achieve optimal weight
Dietary changes
Exercise regularly
Quit smoking
Regular assessment
Risk computation
Computation of 10-year risk for ASCVD 
using a risk-projection algorithm
Not at high risk
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the major modifiable risk factors for ASCVD. The 
treatment goal is stated for each risk factor, along with 
general recommendations on how this goal may be 
achieved. Existing hypertension,7,8 dyslipidaemia,1,6 
and diabetes20-22 treatment guidelines incorporate 
the latest evidence on how to treat these conditions 
and to what appropriate targets. The clinician is 
referred to these guidelines for further guidance. 
Diet
Treatment goal: an overall healthy eating pattern
All patients at increased risk of ASCVD should be 
given advice and specific recommendations for 
eating a healthy diet. Advice should include9:
•	 matching	energy	intake	with	energy	needs;
•	 eating	a	variety	of	fruits,	vegetables,	grains,	low-	
or non-fat dairy products, legumes, fish, poultry, 
and lean meats;
•	 reducing	saturated	and	trans	fats	to	<10%	of	total	
daily caloric intake, through replacement with 
polyunsaturated fats (vegetables, nuts, seeds, and 
seafood);
•	 reducing	cholesterol	intake;
•	 reducing	salt	intake;	and
•	 limiting	 alcohol	 intake	 to	 no	 more	 than	 two	
drinks per day for men and one drink per day for 
women.
Physical activity
Treatment goal: a minimum of 30 minutes of 
moderate-intensity physical activity at least 5 times 
a week, or a minimum of 15 minutes of vigorous-
intensity physical activity at least 5 times a week9
•	 ‘Moderate	 intensity’	 is	 defined	 as	 exercising	 at	
64% to 76% of maximum heart rate (ie 220 minus 
age); activities include brisk walking, slow cycling, 
vacuuming, gardening, golf, tennis (doubles), 
ballroom dancing, and water aerobics.9 ‘Vigorous 
intensity’ is defined as exercising at 77% to 93% 
of maximum heart rate; activities include race 
walking, jogging or running, bicycling, heavy 
gardening, swimming laps, and tennis (singles).9
•	 The	practice	of	the	popular	Chinese	soft	martial	
art tai chi may also be beneficial for individuals at 
risk of ASCVD. A systematic review has shown 
that tai chi has physiological and psychosocial 
benefits, and it also appears to be safe and 
effective in promoting flexibility, balance control, 
and cardiovascular fitness in older patients with 
chronic conditions.23
•	 All	patients	should	consult	their	doctor	prior	to	
initiating graded exercise programmes.
Overweight/obesity
Treatment goal: maintenance of normal body mass 
index and waist circumference
•	 Normal	body	mass	 index	 is	18.5-22.9	kg/m2 for 
Asians,24 and normal waist circumference is 
<90 cm (35.4 inches) for men and <80 cm (31.5 
inches) for women.25
•	 Patients	 who	 are	 overweight	 or	 obese	 should	
strive to achieve normal body weight by 
restricting caloric intake and increasing physical 
activity.
•	 Drug	 therapy	 or	 surgical	 interventions	 may	 be	
a helpful adjunct for the treatment of severe 
obesity in some patients.
Smoking
Treatment goal: complete smoking cessation
•	 Assess	the	patient’s	tobacco	use	and	strongly	urge	
the patient to stop smoking.
•	 Determine	 the	 patient’s	 degree	 of	 nicotine	
addiction and his/her readiness to quit smoking. 
For patients identified as willing to quit, a 
plan should be developed that may involve 
pharmacotherapy, counselling, cessation support 
mechanisms (eg follow-up calls and visits), 
and referral to specialised programmes, if 
available.20,26
Hypertension
Risk factor reduction goal: blood pressure of <140/90 
mm Hg for the general population aged <60 years, 
including patients with previous stroke or transient 
ischaemic attack; patients with coronary heart 
disease; and patients with chronic kidney disease. 
For patients with diabetes, a target blood pressure 
of <140/85 mm Hg is recommended. For the general 
population aged ≥60 years, a target blood pressure 
of <150/90 mm Hg is recommended7-9
•	 Patients	 with	 a	 systolic	 BP	 of	 ≥130	mm	Hg	 or	
diastolic BP of ≥80 mm Hg should be given advice 
and specific recommendations on reducing 
lifestyle risk factors.
•	 Patients	 who	 do	 not	 meet	 their	 primary	 goals	
as defined above should be given drug therapy 
tailored to their circumstances.
•	 The	 choice	 of	 first-line	 therapy	 is	 the	
prerogative of the attending physician. Suitable 
antihypertensive drugs include calcium channel 
blockers, angiotensin-converting enzyme (ACE) 
inhibitors, and angiotensin receptor blockers 
(ARBs), either alone or in combination (Tables 
1 and 2).7,9 Diuretics (chlorthalidone and 
indapamide) and β-blockers may also be used, but 
their long-term use is associated with increased 
risk of new-onset diabetes30,31; of note, there is no 
evidence that hydrochlorothiazide—one of the 
most commonly prescribed antihypertensives—
in its usual dose of 12.5 to 25 mg daily reduces 
myocardial infarction, stroke, or death.32 
•	 When	 target	 BP	 cannot	 be	 achieved	 with	
monotherapy or with a two-drug combination, 
#  Prevention of atherosclerotic cardiovascular disease  # 
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doses can be increased; if target BP cannot 
be achieved by a two-drug combination at 
full doses, switching to another two-drug 
combination, or adding a third drug, may be 
considered.7-9 In patients with uncontrolled BP 
despite treatment with maximally tolerated doses 
of three antihypertensive medications, addition 
of the aldosterone antagonist spironolactone has 
achieved larger reductions in systolic BP than 
addition of the β-blocker bisoprolol, the alpha-
adrenergic blocker doxazosin, or placebo.33
Dyslipidaemia
Risk factor reduction goal: low-density lipoprotein 
cholesterol level of <3 mmol/L. For patients with 
overt atherosclerotic cardiovascular disease, the 
target level should be <1.8 mmol/L9
•	 Low-density	 lipoprotein	 cholesterol	 (LDL-C)	
reduction decreases cardiovascular events.9
•	 Recommended	 target	 LDL-C	 level	 for	 patients	
stratified by ASCVD risk is as follows:
 o Very high ASCVD risk: LDL-C <1.8 mmol/L, 
or a ≥50% reduction if the baseline is between 
1.8 and 3.5 mmol/L (Table 3)
 o High ASCVD risk: LDL-C <2.6 mmol/L, or a 
≥50% reduction if the baseline is between 2.6 
and 5.1 mmol/L
 o Low-to-moderate ASCVD risk: LDL-C <3.0 
mmol/L9
•	 Patients	 at	 low	 and	 moderate	 risk	 should	 be	
given advice and specific recommendations on 
lowering LDL-C through dietary adjustments, 
increased physical activity, and weight reduction. 
If the target is not met after 6 months, they 
should be given a lipid-lowering agent (Tables 4 
and 5).35 
•	 Patients	at	high	risk	should	immediately	be	started	
on lipid-lowering therapy with a high-intensity 
statin (Tables 4 and 5).35 Importantly, however, 
pharmacokinetic studies have shown that Chinese 
patients achieve a higher plasma concentration of 
statin compared with Caucasians, and this may 
be associated with an increased risk of adverse 
effects.36 Consequently, the maximum approved 
doses of the statins available in Asia are around 
half the maximum approved doses in the United 
States.37 The clinician should, therefore, exercise 
caution when prescribing high-intensity statin 
therapy.
•	 Inhibitors	 of	 proprotein	 convertase	 subtilisin/
kexin type 9 have recently been approved for use 
TABLE 1.  Summary of blood pressure management guidelines7,8,27-29
Abbreviations: ACS = acute coronary syndrome; BP = blood pressure; CHD = coronary heart disease; CKD = chronic kidney disease; eGFR = estimated 
glomerular filtration rate; ESH-ESC = European Society of Hypertension/European Society of Cardiology; HF = heart failure; JNC 8 = Eighth Joint National 
Committee; NICE = National Institute for Health and Care Excellence
Study group Recommended target BP (mm Hg)
2011 NICE Clinical Guideline 
for the Management of 
Hypertension, 2009 Clinical 
Guideline for the Management 
of Type 2 Diabetes, and 2014 
Clinical Guideline for the 
Management of Chronic Kidney 
Disease
2013 ESH-ESC Task Force 
Guideline for the Management 
of Arterial Hypertension
2014 JNC 8 
Guideline for the 
Management of 
High Blood Pressure 
in Adults
2016 Hong Kong 
Cardiovascular 
Task Force 
Recommendations
General population (age 
in years)
Age <80: <140/90
Age ≥80: <150/90
Age <80: <140/90
Age ≥80: <140-150/90 
Age <60: <140/90
Age ≥60: <150/90
Age <60: <140/90
Age ≥60: <150/90
Patients with diabetes <140/80 (<130/80 For people with 
kidney, eye, or cardiovascular 
damage)
<140/85 <140/90 <140/85
Patients with chronic 
kidney disease
<140/90 (<130/80 In patients with 
CKD and diabetes)
<140/90 (systolic BP reading 
<140 should be considered. 
When overt proteinuria is present, 
values <130 may be considered, 
provided that changes in eGFR 
are monitored)
<140/90 <140/90
Patients with CHD, ACS, 
HF
Patients with CHD: <140/90 <140/90 Not specified <140/90
Other special populations 
(age in years) 
Patients identified as having 
a ‘white coat’ effect: consider 
ambulatory or home BP 
monitoring. Aim for usual target 
BP during waking hours of:
Age <80: <135/85
Age ≥80: <145/85
Patients with organ damage: 
<140/90
Not specified Not specified
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in the United Kingdom and the United States 
as an adjunct to diet and maximally tolerated 
statin therapy for the treatment of individuals 
with primary hypercholesterolaemia or mixed 
dyslipidaemia, or those with clinical ASCVD 
who require additional lowering of LDL-C.38,39 
Clinical trials have demonstrated decreases 
in LDL-C by up to 60% in subjects receiving 
these agents38; definitive evidence of reduced 
cardiovascular event rates associated with their 
use may be provided by ongoing trials.
Diabetes
Risk factor treatment goal: glycated haemoglobin 
<7%20-22
•	 All	 diabetic	 patients	 are	 considered	 high	 risk	
for the development of ASCVD9,21 and should 
receive appropriate management upon diagnosis. 
This includes guidance on diet modification 
and increased physical activity in conjunction 
with pharmacotherapy.20-22 Early initiation of 
medication is recommended to avoid any delay 
in treatment. Insulin is administered if treatment 
goals are not achieved with oral therapy.20-22 
Treatment goal for glycaemia should be tailored 
according to the patient profile in order to avoid 
hypoglycaemia in those with co-morbidities or in 
elderly patients.22,40 
•	 In	 diabetic	 patients,	 treat	 other	 ASCVD	
risk factors more aggressively,22 including 
hypertension. Nevertheless, present evidence 
suggests that a BP target of <140/85 mm Hg is 
appropriate in patients with diabetes, with a lower 
Abbreviations: ACE = angiotensin-converting enzyme; AV = atrioventricular ; COPD = chronic obstructive pulmonary disease; LV = left ventricular ; MI = 
myocardial infarction
TABLE 2.  Classes of antihypertensive drugs
Drug class Agents available in 
Hong Kong
Mechanism of action Conditions favouring 
use of drug class
Compelling 
contra-indications
Possible contra-
indications
ACE inhibitors Captopril
Enalapril
Imidapril
Lisinopril
Perindopril 
Quinapril
Ramipril
Blocks conversion 
of angiotensin I to 
angiotensin II by 
inhibiting ACE
Congestive heart 
failure, post-MI 
patients with reduced 
LV ejection fraction, 
diabetes mellitus, renal 
dysfunction
Pregnancy, 
hyperkalaemia, 
bilateral renal artery 
stenosis
-
Alpha-blockers Doxazosin
Prazosin
Blocks α1-adrenoceptors 
in the vasculature, 
causing a clinically 
significant reduction 
in blood pressure as 
a result of a reduction 
in systemic vascular 
resistance
Benign prostatic 
hypertrophy
- Orthostatic hypotension
Angiotensin II 
antagonists
Azilsartan
Candesartan
Eprosartan
Irbesartan
Losartan
Olmesartan
Telmisartan
Valsartan
Blocks angiotensin II  
type I receptors 
Diabetes mellitus, post-
MI patients, patients 
with contra-indications 
to ACE inhibitors, renal 
dysfunction
Pregnancy, 
hyperkalaemia, 
bilateral renal artery 
stenosis
-
Beta-blockers Atenolol
Bisoprolol
Carvedilol
Esmolol
Metoprolol
Nebivolol
Pindolol
Propranolol
Competitively 
antagonises effect 
of catecholamines at 
β-adrenergic receptor 
sites
Angina, post-MI 
patients, congestive 
heart failure, glaucoma
Asthma, AV block Peripheral artery 
disease, metabolic 
syndrome, glucose 
intolerance, physically 
active patients, COPD
Calcium antagonists 
(dihydropyridines)
Amlodipine
Felodipine
Lercanidipine
Nifedipine
Dilates coronary and 
peripheral arteries as 
a result of inhibition of 
cellular Ca2+ influx
Angina, LV hypertrophy - Tachyarrhythmias, heart 
failure
Calcium antagonists Diltiazem
Verapamil
(ditto) (ditto) AV block, heart 
failure
-
Thiazide diuretics Hydrochlorothiazide
Indapamide
Metolazone
Inhibits the Na+/Cl- 
cotransporter in the distal 
tubule
Elderly patients with no 
co-morbid conditions
Gout Metabolic syndrome, 
glucose intolerance, 
pregnancy
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BP (systolic BP of <130 mm Hg) as an option in 
patients with hypertension and nephropathy. It 
should be noted that lower BP may be associated 
with increased risk of adverse events, especially 
TABLE 3.  Summary of lipid management goals6,9,34
TABLE 4.  Agents recommended for achieving lipid-lowering goals6,9,34
Abbreviations:  ACC/AHA = American College of Cardiology/American Heart Association; ASCVD = atherosclerotic cardiovascular disease; CKD = chronic 
kidney disease; CV = cardiovascular ; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; NICE = National Institute 
for Health and Care Excellence; SCORE = Systematic Coronary Risk Evaluation
Abbreviations:  ACC/AHA = American College of Cardiology/American Heart Association; BAS = bile acid sequestrant; CKD = chronic kidney disease;  
FH = familial hypercholesterolaemia; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; NICE = National Institute 
for Health and Care Excellence
* Moderate-to-high-intensity statin: Expected to reduce LDL-C by 30%-50%, eg atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, 
pravastatin 40-80 mg, lovastatin 40 mg
† High-intensity statin: Expected to reduce LDL-C by ≥50%, eg atorvastatin 40-80 mg, rosuvastatin 20-40 mg
Recommended lipid levels (mmol/L or % reduction)
2016 European Guidelines on 
Cardiovascular Disease Prevention 
in Clinical Practice
2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol 
to Reduce Atherosclerotic 
Cardiovascular Risk in Adults
2014 NICE Clinical 
Guideline on Lipid 
Modification
2016 Hong Kong 
Cardiovascular 
Task Force 
Recommendations
Primary prevention LDL-C <1.8 to <3.0 mmol/L according 
to SCORE risk 
↓LDL-C ≥30% if 10-year risk 
≥7.50%
↓Non HDL-C ≥40% LDL-C <1.8 mmol/L to 
<3.0 mmol/L according 
to individual CV risk 
level
Secondary prevention LDL-C <1.8 mmol/L or ↓LDL-C ≥50% ↓LDL-C ≥50% ↓Non HDL-C ≥40% LDL-C <1.8 mmol/L
Familial hyper-
cholesterolaemia
No recommendation ↓LDL-C ≥50% ↓Non HDL-C ≥40% LDL-C <2.5 mmol/L
Diabetes LDL-C <1.8 mmol/L or ↓LDL-C ≥50% ↓LDL-C ≥50% if 10-year ASCVD 
risk ≥7.50%
or
↓LDL-C ≥30-50% 
↓Non HDL-C ≥40% LDL-C <1.8 mmol/L to 
2.5 mmol/L
According to individual 
CV risk level
CKD Severe:
LDL-C <1.8 mmol/L or ↓LDL-C ≥50%
Moderate:
LDL-C <2.6 mmol/L or ↓LDL-C ≥50%
No target specified ↓Non HDL-C ≥40% LDL-C <1.8 mmol/L to 
2.5 mmol/L
According to individual 
CV risk level
Recommended lipid-lowering agents
2016 European Guidelines 
on Cardiovascular Disease 
Prevention in Clinical Practice9
2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol 
to Reduce Atherosclerotic 
Cardiovascular Risk in Adults6
2014 NICE Clinical Guideline on Lipid 
Modification
Primary prevention Statin 10-Year risk ≥7.5%: moderate*- to 
high†-intensity statin
10-Year risk ≥10%: atorvastatin 20 mg
Age ≥85 years: consider atorvastatin 20 mg
Secondary prevention Statin ≤75 Years: high-intensity statin†
>75 Years: moderate statin*
Atorvastatin 80 mg
Familial hyper-
cholesterolaemia
Statin High-intensity statin† Atorvastatin 20 mg
Consider ezetimibe for FH
Diabetes Statin 10-Year risk ≥7.5%: high-intensity statin†
10-Year risk <7.5%: moderate-intensity 
statin*
Type 1: consider atorvastatin 20 mg
Type 2 and 10-year risk ≥10%: atorvastatin 
20 mg
CKD Statin No specific recommendation Atorvastatin 20 mg
If non–HDL-C ↓ <40%: consider higher 
dose
Combination with 
non-statin
If target not reached with highest 
tolerated statin
If target not reached with highest 
tolerated statin
Do not offer fibrate, niacin, BAS, or 
omega-3 fatty acid
in older patients or those with a long duration 
of diabetes, and the risk and benefit of intensive 
BP lowering needs to be considered individually 
according to the patient profile.22
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Abbreviations: HDL-C = high-density lipoprotein cholesterol; HMG-CoA = 3-hydroxy-3-methyl coenzyme A; LDL-C = low-density lipoprotein cholesterol; 
MI = myocardial infarction;  VLDL = very-low-density lipoproteins
TABLE 5.  Classes of lipid-lowering agents
Drug class Agents available 
in Hong Kong
Mechanism of action Conditions favouring 
use of drug class
Compelling contra-
indications
Possible contra-
indications
Statins Atorvastatin
Fluvastatin
Lovastatin
Pravastatin
Rosuvastatin
Simvastatin
Inhibit the enzyme HMG-
CoA reductase, which 
plays a central role in 
cholesterol synthesis 
Existing 
cardiovascular 
disease, very high 
LDL-C levels, 
diabetes, patients with 
a high 10-year risk 
of MI
Should not be used in 
patients with active or 
chronic liver disease, or 
by pregnant or lactating 
women
Liver function should 
be tested before, 
after 6-12 weeks of 
therapy, and with 
any dose increase. 
Advise patient to 
consult immediately if 
signs of muscle pain 
suggesting myopathy 
occur
Fibrates Bezafibrate
Fenofibrate
Gemfibrozil
Varies depending on 
the agent. Bezafibrate, 
fenofibrate reduce the 
concentration of VLDL 
by increasing the activity 
of lipoprotein lipase. 
Gemfibrozil inhibits 
lipolysis, reduces hepatic 
fatty acid uptake, and 
reduces secretion of VLDL 
from the liver
Very high levels of 
plasma triglycerides
Not recommended in 
patients with severe renal 
or hepatic impairment, 
hypoalbuminaemia, 
primary biliary cirrhosis, 
gallbladder disease, or 
nephrotic syndrome.
Should not be used by 
pregnant or lactating 
women
Use with caution in 
mild-to-moderate renal 
impairment; monitor 
serum transaminase 
levels regularly.
May cause myalgia, 
myopathy.
Rarely used with 
statins, may interact 
with anticoagulant 
therapy
Bile-acid sequestrants 
(resins)
Cholestyramine Binds with bile acids 
to form an insoluble 
complex that is excreted 
in the faeces. The 
increasing loss of bile acid 
increases the oxidation of 
cholesterol to bile acids
Patients for whom 
statin therapy is 
contra-indicated or 
those who cannot 
tolerate statin therapy
Contra-indicated 
in complete biliary 
obstruction, high fasting 
triglycerides
May decrease folate 
levels
Selective cholesterol 
absorption inhibitor
Ezetimibe Localises in the brush 
border of the small 
intestine where it inhibits 
absorption of cholesterol, 
decreasing its delivery to 
the liver. This decrease in 
cholesterol stored in the 
liver increases cholesterol 
clearance from the blood
Patients for whom 
statin therapy is 
contra-indicated or 
those who cannot 
tolerate statin therapy
Active liver disease.
Should not be used by 
pregnant or lactating 
women
Use with caution in 
patients with renal or 
hepatic impairment
Combination 
cholesterol absorption 
inhibitor and statin
Ezetimibe-
simvastatin
Simvastatin inhibits the 
HMG-CoA reductase 
enzyme and thus 
cholesterol synthesis, 
while ezetimibe inhibits 
cholesterol absorption 
in the small intestine, 
reducing liver cholesterol 
stores and increasing 
cholesterol clearance from 
the blood
Patients who 
cannot achieve 
target LDL-C levels 
despite receiving the 
maximum tolerated 
statin dose
Contra-indications 
include hypersensitivity, 
active liver disease or 
unexplained persistent 
elevations of serum 
transaminases, 
pregnancy and lactation, 
and concomitant 
administration of potent 
CYP3A4 inhibitors, 
gemfibrozil, cyclosporine 
or danazol
-
Nicotinic acid Nicotinic acid The exact mechanisms 
are currently unknown, but 
are not related to its role 
as a vitamin
Patients who cannot 
tolerate statin therapy, 
and for those with 
very low levels of 
HDL-C and/or high 
triglyceride levels
Contra-indications include 
hypersensitivity reactions 
to nicotinic acid, liver 
disease, impaired glucose 
tolerance, diabetes 
mellitus, and gouty 
arthritis
-
Discussion
The gap between evidence and practice
Although clear, evidence-based guidelines and 
recommendations for ASCVD prevention have 
been available for a number of years and are 
regularly updated, there is evidence that they are 
not routinely implemented in clinical practice.9,41,42 
For example, Yusuf et al43 reported worldwide poor 
use of medications for the secondary prevention of 
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ASCVD. Their study included 153 996 adults aged 
35 to 70 years from rural and urban communities 
in high-, upper-middle−, lower-middle−, and 
low-income countries, 5650 of whom had had a 
self-reported CHD event and 2292 a stroke. Few 
individuals with ASCVD took antiplatelet drugs 
(25.3%), β-blockers (17.4%), ACE inhibitors or ARBs 
(19.5%), or statins (14.6%). As expected, drug use 
was higher in high-income countries, with 11.2% of 
patients in these countries not receiving any drugs 
compared with 45.1% of patients in upper-middle−
income countries, 69.3% in lower-middle−income 
countries, and 80.2% in low-income countries. 
Notably, despite the relative accessibility of drugs 
for secondary prevention of ASCVD in high- and 
upper-middle−income countries, many patients 
remained untreated.
 Of the patients who do receive treatment for 
ASCVD risk factors, only a few attain their treatment 
goals. Findings from the Hong Kong Cardiovascular 
Task Force Risk Management Programme indicate 
that 84% of enrolled hypertensive patients were 
treated with one or two antihypertensive drugs, 
most commonly ARBs (63.5%) and calcium channel 
blockers (47.2%; BMY Cheung, unpublished data). 
Similarly 64% of the diabetic patients were treated 
with metformin (68.8%) and/or gliptins (36%), while 
78.1% of patients with dyslipidaemia were treated 
with a statin. Notably, however, treatment goals for 
hypertension (<130/80 mm Hg for diabetic patients, 
<140/90 mm Hg for non-diabetics) and diabetes 
(glycated haemoglobin <7%) were met by just over 
50% of hypertensive patients and approximately 60% 
of diabetics. 
 Ensuring physician compliance with 
evidence-based guidelines and improving clinician 
understanding of factors affecting patient compliance 
with treatment may be the key to decreasing ASCVD 
risk in the Hong Kong population.
Differences between the 2008 and 2016 
consensus statements
The present update of the 2008 Consensus 
Statement introduces the use of the new American 
Pooled Cohort Risk Assessment Equations that 
have superseded the Framingham Risk Evaluation; 
ASCVD risk can be assessed using either these 
equations or the European SCORE system to 
stratify patients into low-, moderate-, or high-risk 
categories to aid targeting of therapies as well as 
the establishment of suitable treatment goals. The 
risk factor reduction goals for hypertension and 
dyslipidaemia have been updated to reflect the 
most current recommendations from the Eighth 
Joint National Committee, the European guidelines 
on the management of arterial hypertension, and 
the European guidelines on cardiovascular disease 
prevention in clinical practice. The HDL-C target 
included in the 2008 Consensus Statement has 
been omitted from the current update as increased 
HDL-C has not been proven to reduce ASCVD risk. 
Conclusions
The development of ASCVD in at-risk patients 
may be slowed and/or prevented by lifestyle 
modification, reduction of metabolic risk factors, 
and pharmacological treatment. The clinician plays 
a central role in ASCVD prevention—identifying 
at-risk patients, calculating the total ASVCD risk 
score, encouraging lifestyle changes, and providing 
targeted interventions to achieve specific treatment 
goals. Nonetheless, it is vital that the clinician is not 
overly focused on the treatment of isolated ASCVD 
risk factors but should instead adopt a ‘whole-
person’ approach to diagnosis and therapy. Many 
patients present with multiple risk factors and, 
therefore, individualised, nuanced patient evaluation 
and management is essential to achieve optimum 
outcomes. Finally, none of these interventions will 
result in ASVCD prevention without the cooperation 
of the patient. Clinicians are encouraged to build 
strong partnerships with their patients, with the 
aim of establishing individual ownership of their 
treatment plans and, thus, improved treatment 
compliance.
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